Quick Answer
Eloxx Pharmaceuticals, Inc. reported Net Income of -$6.00 million for fiscal year 2025.
Eloxx Pharmaceuticals, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$6.00M | -90.7% |
| 2024 | -$3.14M | +81.6% |
| 2023 | -$17.05M | +52.7% |
| 2022 | -$36.06M | +46.0% |
| 2021 | -$66.73M | -93.0% |
| 2020 | -$34.58M | +32.0% |
| 2019 | -$50.87M | -7.8% |
| 2018 | -$47.19M | -122.4% |
| 2017 | -$21.21M | -266.0% |
| 2017 | -$5.80M | +41.1% |
| 2016 | -$9.85M | -19.1% |
| 2016 | -$8.27M | -29.1% |
| 2015 | -$6.41M | +64.5% |
| 2015 | -$18.06M | -95.8% |
| 2014 | -$9.23M | -50.7% |
| 2013 | -$6.12M | -20.9% |
| 2012 | -$5.07M | +30.3% |
| 2011 | -$7.27M | +45.7% |
| 2010 | -$13.38M | -133.7% |
| 2009 | -$5.73M | -24.5% |
| 2008 | -$4.60M | -41.5% |
| 2007 | -$3.25M | +1.9% |
| 2006 | -$3.31M | -11.3% |
| 2005 | -$2.98M | +20.1% |
| 2004 | -$3.73M | -34.2% |
| 2003 | -$2.78M | +8.1% |
| 2002 | -$3.02M | -48.6% |
| 2001 | -$2.03M | +39.2% |
| 2000 | -$3.35M | -186.3% |
| 1999 | -$1.17M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2023 | -$3.59M | +52.2% | +17.3% |
| June 30, 2023 | -$4.34M | +59.1% | +30.3% |
| March 31, 2023 | -$6.23M | +46.4% | +17.0% |
| September 30, 2022 | -$7.51M | +24.0% | +29.3% |
| June 30, 2022 | -$10.62M | +70.6% | +8.6% |
| March 31, 2022 | -$11.62M | -33.7% | -17.6% |
| September 30, 2021 | -$9.88M | -49.4% | +72.6% |
| June 30, 2021 | -$36.06M | -357.2% | -314.7% |
- Eloxx Pharmaceuticals, Inc. showed a decrease of -90.7% in Net Income compared to the prior fiscal year.
- Over the 1999–2025 period, Eloxx Pharmaceuticals, Inc.’s net income has declined by 412.8% (from -$1.17 million to -$6.00 million).
- The most recent figure is from Eloxx Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: